Our Story


The birth of Hetero Biopharma in 2009 marked a new era in the field of biopharmaceuticals. An R&D unit was established, and within a short time, the company became a manufacturer of affordable medicines accessible to people worldwide.

Our Story


The state-of-the-art manufacturing facility that was built in 2011 was equipped with the latest technology and equipment, ensuring that the highest quality medicines were produced.

Our Story


In 2014, Hetero Biopharma launched its first biosimilar product, Derise (Darbepoetin alfa), a biosimilar to Aranesp®. We are also the second company in the world to launch a Darbepoetin biosimilar.

Our Story


Hetero Biopharma entered the global market with the launch of Bevaas (Bevacizumab, a biosimilar to Avastin®). It received PIC/S member country approval for the manufacturing unit.

Our Story


Adalimumab solution for injection was launched in PFS as a biosimilar to Humira®. The commissioning of an additional manufacturing unit has been completed.

Our Story


  • The clinical evaluation of anti-HER-2 mAb is currently in progress.
  • The filing of biosimilars in a regulated market is also underway.

Our Story

Product Launches
Between 2017-2023

  • Adalimumab
  • Trastuzumab
  • Tocilizumab
  • Pegaspargase
  • L-Asparaginase
  • Tenecteplase

Enabling a future
where hope and
access thrive

Hetero Biopharma Expertise

Monoclonal antibodies (mAbs)

Recombinant proteins




Single-use solutions

Small molecule products

Power of Biosimilars


The Biologics or biosimilars are
produced using a unique cell line and
a proprietary process that varies
from one manufacturer to another.

Our Core

The year 2009, Hetero’s vertically integrated
biologics venture began with a focus on
key biosimilars through its Hetero
Research Foundation (HRF).

high quality human biotechnology

Our Insignia

The Hetero Biopharma Insignia is an apt interplay of DNA and an hourglass. Together, they represent 'life' and 'time' thereby signifying Hetero's foray into modern biopharmaceuticals by not just offering high-quality human biotechnology products but also focusing on their early commercialization to help reach a wider audience, leading to a healthier tomorrow for everybody in this world.